|
1
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
J Natl Cancer Inst
|
2006
|
2.61
|
|
2
|
What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).
|
Cancer Invest
|
2003
|
1.49
|
|
3
|
Medical and nursing education and training opportunities to improve survivorship care.
|
J Clin Oncol
|
2006
|
1.32
|
|
4
|
Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer.
|
Am J Clin Oncol
|
2003
|
0.75
|